Rituximab
- Generic Name
- Rituximab
- Brand Names
- MabThera, Riabni, Rituxan, Rituxan Hycela, Ruxience, Truxima, Blitzima, Rixathon, Riximyo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 174722-31-7
- Unique Ingredient Identifier
- 4F4X42SYQ6
- Background
Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences , . It was originally approved by the U...
- Indication
Rituximab is indicated for the treatment of adult patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin’s Lymphoma (NHL) as a single agent. Also, it is indicated for the treatment of adult patients with previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in pat...
- Associated Conditions
- Active, Moderate to Severe Rheumatoid Arthritis, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Non-Hodgkin's Lymphoma, Granulomatosis With Polyangiitis, Microscopic Polyangiitis (MPA), Advanced Burkitt Lymphoma (BL), Advanced Burkitt-like lymphoma, Advanced Diffuse Large B-Cell Lymphoma (DLBCL), Advanced Mature B-cell type acute leukaemia, Moderate Pemphigus Vulgaris (PV), Non-progressive Low Grade Non-Hodgkin's Lymphoma (NHL), Refractory Low Grade Non-Hodgkin's Lymphoma (NHL), Refractory follicular B-cell non-Hodgkin's lymphoma, Relapsed Low Grade Non-Hodgkin's Lymphoma (NHL), Relapsed follicular B-cell non-Hodgkin's lymphoma, Severe Pemphigus Vulgaris (PV)
- Associated Therapies
- -
Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL
- First Posted Date
- 2024-07-08
- Last Posted Date
- 2024-07-08
- Target Recruit Count
- 89
- Registration Number
- NCT06489808
- Locations
- 🇨🇳
Institute of Hematology & Blood Disease Hospital, Tianjin, Tianjin, China
Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL
- Conditions
- Interventions
- First Posted Date
- 2024-06-26
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 15
- Registration Number
- NCT06475235
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL
- First Posted Date
- 2024-06-21
- Last Posted Date
- 2024-06-21
- Target Recruit Count
- 20
- Registration Number
- NCT06468943
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Nanjing, China
Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL
- Conditions
- Interventions
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 152
- Registration Number
- NCT06441097
A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-05-22
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Celgene
- Target Recruit Count
- 90
- Registration Number
- NCT06425302
- Locations
- 🇺🇸
Local Institution - 0020, New Brunswick, New Jersey, United States
🇩🇪Gemeinschaftspraxis Hämatologie - Onkologie Freiberg-Richter, Jacobasch, Illmer, Wolf, Dresden, Germany
🇮🇹Local Institution - 0179, Rozzano, Milano, Italy
MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.
- Conditions
- Interventions
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 60
- Registration Number
- NCT06412497
- Locations
- 🇺🇸
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States
Belimumab After Rituximab in Resistant Primary Juvenile SS
- Conditions
- Interventions
- First Posted Date
- 2024-05-13
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT06410833
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Iptacopan in Patients With ANCA Associated Vasculitis
- Conditions
- Interventions
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 78
- Registration Number
- NCT06388941
- Locations
- 🇹🇷
Novartis Investigative Site, Pendik Istanbul, Turkey
Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL)
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 66
- Registration Number
- NCT06364423
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Global Phase 3 Study of Orelabrutinib+BR vs.BR in Pts With TN MCL
- Conditions
- Interventions
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- InnoCare Pharma Inc.
- Target Recruit Count
- 490
- Registration Number
- NCT06363994
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.